Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

Improving the standard of clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAb) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:bioRxiv
Autores principales: Martinez, David R., Schaefer, Alexandra, Leist, Sarah R., Li, Dapeng, Gully, Kendra, Yount, Boyd, Feng, Joy Y., Bunyan, Elaine, Porter, Danielle P., Cihlar, Tomas, Montgomery, Stephanie A., Haynes, Barton F., Baric, Ralph S., Nussenzweig, Michel C., Sheahan, Timothy P.
Formato: Artigo
Lenguaje:Inglês
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7852229/
https://ncbi.nlm.nih.gov/pubmed/33532765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.01.27.428478
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares